Meeting
2019 ASCO Annual Meeting
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
Authors
Georgina V. Long
Melanoma Institute Australia, University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, Australia
Georgina V. Long , Caroline Robert , Marcus O. Butler , Felix Couture , Matteo S. Carlino , Steven O'Day , Victoria Atkinson , Jonathan S. Cebon , Michael Paul Brown , Stéphane Dalle , Andrew Graham Hill , Geoffrey Thomas Gibney , Steven L. McCune , Alexander M. Menzies , Cuizhen Niu , Nageatte Ibrahim , Blanca Homet Moreno , Adi Diab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02089685
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9514)
DOI
10.1200/JCO.2019.37.15_suppl.9514
Abstract #
9514
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2015 ASCO Annual Meeting
Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.
First Author: Michael B. Atkins
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
First Author: Dirk Schadendorf